EN DE
Watch Lytix Biopharma AS for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Lytix Biopharma AS (LYTIX) fair value: what the stock is really worth

As of Oct 28, 2026: fair value (intrinsic value) of Lytix Biopharma AS stock NOK 0.78, price NOK 7.50, upside -89.6%, quality 47 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value 30%+ above price?No
  2. Quality 50+?No
  3. In an uptrend?Yes
  4. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare NO · ISIN NO0010405780

LB Lytix Biopharma AS logo Thin data Oct 29, 2026

Lytix Biopharma AS

LYTIX · OL

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 90% below what the stock costs today.

Quality 47/100
Mixed Growth (revenue 5y +104.7 %/yr in NOK)
Fair value kr 0.7800 · Strongly overvalued (−89.6%)
Negative free cash flow
Trails peers (2/6)
Narrow moat 12/100 · thin data
Thin data
Watch Lytix Biopharma AS for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 15.00 kr 4.68 Fair Value kr 0.7800 Aug 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.

How to read this chart

60‑month range kr 4.68 – kr 15.00 · fair‑value band kr 0.5100 – kr 0.9700 · the kr 7.50 price screens above the kr 0.7800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.

Follow Lytix Biopharma AS in your weekly email

Every Wednesday you see whether Lytix Biopharma AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States.

Show moreShow less

Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab.

The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases.

It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of ruxotemitide for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma ASA was founded in 2003 and is based in Oslo, Norway.

Stock analysis

Lytix Biopharma AS (LYTIX) currently trades at kr 7.50, while our model-based Fair Value estimate is kr 0.7800, 89.6% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: kr 0.5100 (bear) to kr 0.9700 (bull), the price of kr 7.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Lytix Biopharma AS reported revenue of 0 NOK in FY2025 versus 17.0K NOK in FY2021. Reported net income was −60.0M NOK in FY2025.

Key figures

Market cap 594M NOK (≈ $64.1M) Micro · EPS (TTM) kr −1.33 · Return on equity −107% · Return on assets (EBIT) −72.5% · Revenue (TTM) 377K NOK · Free cash flow −59.9M NOK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 35% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −90%, LYTIX screens richer than that median.

Fair Value models

Bear kr 0.5100 Fair Value kr 0.7800 Bull kr 0.9700
Price kr 7.50 · Upside -89.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) kr 0.5100 kr 0.7800 kr 0.9700 52
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.5100 kr 0.7800 kr 0.9700 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 4
Are margins and returns getting better?
Cashflow 67
Do the profits arrive as real cash?
Financial strength 81
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 60
How calm the share price moves, does not count
Momentum 30
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 18
Distance to the 52-week high, does not count
New shares 39
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+179.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+768.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+104.7%
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10,890.6% (2019) → −861.3% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

LYTIX screens overvalued: fair value 90% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Lytix Biopharma AS with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 597 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 47 · Above median
Fair Value upside −89.6% · Bottom 25%
Profitability
Return on assets −73.6% · Bottom 25%
Operating margin (12 months) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 9.61× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $816.10 $1,275 +56% vs LYTIX
Vertex Pharmaceuticals Incorporated VRTX $517.49 $569.24 +10% vs LYTIX
Samsung Biologics Co 207940 1,374,000 KRW 1,511,400 KRW +10% vs LYTIX
WuXi Biologics (Cayman) Inc 2269 HK$45.80 HK$50.38 +10% vs LYTIX
argenx SE ARGX $882.48 $908.40 +3% vs LYTIX
Alnylam Pharmaceuticals, Inc ALNY $227.66 $217.88 −4% vs LYTIX
CSL Limited CSL A$196.78 A$178.75 −9% vs LYTIX
BeOne Medicines AG ONC $370.87 $254.12 −31% vs LYTIX
Celltrion, Inc 068270 188,600 KRW 74,944 KRW −60% vs LYTIX
Royalty Pharma plc RPRX $64.76 $19.01 −71% vs LYTIX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lytix Biopharma AS · Fair Value
kr 0.7800 −90%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Lytix Biopharma AS Fair Value". https://www.fairvalue-calculator.com/stock/LYTIX

Frequently asked questions

Is Lytix Biopharma AS (LYTIX) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of kr 0.7800 versus a price of kr 7.50, about −90% upside (overvalued).
What is the fair value of LYTIX?
Our model-based fair value for Lytix Biopharma AS is kr 0.7800 (as of Oct 29, 2026), built from audited fundamentals. The current price: kr 7.50.
What is the quality score of LYTIX?
Lytix Biopharma AS has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lytix Biopharma AS (LYTIX)?
Our model-based price target is the fair value of kr 0.7800 (as of Oct 29, 2026) from 1 valuation models. Cautious scenario kr 0.5100, optimistic scenario kr 0.9700. It is a calculation from audited fundamentals, not an analyst target.
What is the Lytix Biopharma AS stock forecast for 2026?
Our models put fair value at kr 0.7800, about −90% upside versus a price of kr 7.50 (overvalued). Cautious scenario kr 0.5100, optimistic scenario kr 0.9700. The calculation is refreshed regularly with new filings.
What is the revenue of Lytix Biopharma AS (LYTIX)?
Lytix Biopharma AS reported trailing-twelve-month revenue of about 377K NOK (latest available figure, as of Oct 29, 2026).
What is the intrinsic value of Lytix Biopharma AS (LYTIX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lytix Biopharma AS it is kr 0.7800 per share (as of Oct 29, 2026), against a price of kr 7.50. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Lytix Biopharma AS stock overvalued or undervalued in 2026?
As of Oct 29, 2026, LYTIX trades above its calculated fair value: price kr 7.50, fair value kr 0.7800, a gap of about −90% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LYTIX?
No. The price is what the market pays today (kr 7.50); the fair value is what the company's own numbers justify (kr 0.7800). For Lytix Biopharma AS the two are kr 6.72 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lytix Biopharma AS worth?
The market values Lytix Biopharma AS at about 594M NOK (market capitalisation, as of Oct 29, 2026). Per share that is kr 7.50; our models calculate a fair value of kr 0.7800 per share.
What do the bullish and bearish scenarios say about LYTIX?
Our models span a range for Lytix Biopharma AS: cautious scenario kr 0.5100, base kr 0.7800, optimistic kr 0.9700 per share (as of Oct 29, 2026, price kr 7.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Lytix Biopharma AS (LYTIX)?
Balance-sheet figures for Lytix Biopharma AS (as of Oct 29, 2026): return on equity −107.1%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is LYTIX from its 52-week high?
Lytix Biopharma AS trades at kr 7.50, about 35% below its 52-week high of kr 11.50 and at the low of kr 7.50 (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.7800 is for.
Which stocks are comparable to Lytix Biopharma AS?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lytix Biopharma AS stock attractive at the current price?
The data as of Oct 29, 2026: price kr 7.50, calculated fair value kr 0.7800 (−90%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LYTIX calculated?
We run Lytix Biopharma AS through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.7800, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Lytix Biopharma AS itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lytix Biopharma AS (LYTIX)?
The closing price on Oct 28, 2026 was kr 7.50. Our model-based fair value is kr 0.7800, about −90% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lytix Biopharma AS right now?
The price sits above even our optimistic bull case (kr 0.9700). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 0.5100 to kr 0.9700) leaves room in how you read the outcome.

Key figures of Lytix Biopharma AS

How large is the market capitalisation of Lytix Biopharma AS (LYTIX)?
The market capitalisation of Lytix Biopharma AS is 594M NOK (≈ $64.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Lytix Biopharma AS (LYTIX)?
Earnings per share at Lytix Biopharma AS are kr −1.33. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Lytix Biopharma AS (LYTIX)?
The return on equity (ROE) of Lytix Biopharma AS is −107% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lytix Biopharma AS (LYTIX)?
On an EBIT basis the return on assets of Lytix Biopharma AS is −72.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Lytix Biopharma AS (LYTIX) generate?
The free cash flow of Lytix Biopharma AS is −59.9M NOK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Lytix Biopharma AS in the live analysis

One click puts Lytix Biopharma AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.